Eli Lilly (LLY)
$139.07 2.14 (1.52%)
18:29 EST LLY Stock Quote Delayed 15 Minutes
Previous Close $139.07
Market Cap 150.95B
PE Ratio 129.97
Volume (Avg. Vol.) 3.18M
Day's Range 138.70 - 141.99
52-Week Range 101.36 - 142.25
Dividend & Yield 2.25 (1.62%)
LLY Stock Predictions, Articles, and Eli Lilly News
- From InvestorPlace
- From the Web
Roku shares fall as its CFO resigns. Here's what else happened in the stock market today, as bulls search for new highs.
Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock. So, after the cash raise torpedoed the....
These big stock charts highlight three value plays left behind in the market's shift away from growth stocks.
Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.
Stock charts of LLY, HIG and GIS are moving into the midpoint of the week on the verge of major moves.
Eli Lilly, Alexion and AbbVie are just some of the top healthcare stocks to buy here, now that disappointing news has driven them to cheap prices.
The stock charts of Eli Lilly, SYSCO and Interpublic Group are knocking on the door of some trade-worthy moves.
The stock charts of LLY, BA and HRB are moving into pivotal positions as the trading week starts to wind down.
The stock charts of HRL, JNPR and LLY stock are moving into the midpoint of the week on the cusp of something trade-worthy.
Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
The bull thesis in Eli Lilly stock has strong qualitative and quantitative support, making it pretty hard to refute or ignore.
A recent article in the investment media asked if Pfizer stock was a better buy than Eli Lilly stock. Here’s why I wouldn’t buy either.
In 2018, Humalog generated $3.0 billion for Eli Lilly, 5% higher than a year earlier. Assuming Humalog’s gross margin is 73.8% (I’m using the company’s overall gross margin; it’s likely higher), Eli Lilly had $2.2 billion in gross profits from this single drug. Except for Trulicity, the company’s bestselling diabetes drug, Humalog is the company’s second-largest revenue and profit generator.
The stock charts of PPL, CF and DHI are all on the precipice of major moves, though each one has one more hurdle to clear.
The stock charts of LLY, LKQ and CNC deserve a closer look through a technical trading lens as the trading week winds down.
Options trading was abuzz in Eli Lilly, Twitter and Freeport-McMoRan on Wednesday. Here are the metrics and levels that matter here.
Navellier RatingsPowered by Portfolio Grader